Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Theravance Bio Ord
(NQ:
TBPH
)
9.470
-0.140 (-1.46%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Theravance Bio Ord
< Previous
1
2
3
4
5
6
Next >
Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics
March 12, 2024
Although the bears see cynical opportunities, you can make give them a taste of their own medicine with these short-squeeze stocks.
Via
InvestorPlace
Earnings Scheduled For February 26, 2024
February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
Via
Benzinga
A Preview Of Theravance Biopharma's Earnings
February 23, 2024
Via
Benzinga
Theravance Biopharma Earnings Preview
August 04, 2023
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Unveiling 4 Analyst Insights On Theravance Biopharma
September 16, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Theravance Biopharma
August 06, 2024
Via
Benzinga
TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024
August 05, 2024
TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
June 12, 2024
Via
Benzinga
TBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024
May 13, 2024
TBPH stock results show that Theravance Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
BTIG Research Predicts Over 118% Rally for These 3 Stocks
April 15, 2024
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.
Via
InvestorPlace
Recap: Theravance Biopharma Q4 Earnings
February 26, 2024
Via
Benzinga
Earnings Preview: Theravance Biopharma
February 24, 2023
Via
Benzinga
Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
January 23, 2024
U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Shares of Applied Therapeutics, Inc.
Via
Benzinga
Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today?
January 05, 2024
Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 05, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 05, 2024
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!
Via
InvestorPlace
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 05, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
7 Short-Squeeze Stocks That Are Screaming for Speculation
December 24, 2023
If you like to march to your own beat even against high pressure, these short-squeeze stocks could be right for you.
Via
InvestorPlace
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
November 18, 2023
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...
Via
Talk Markets
Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
November 08, 2023
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Stocks That Hit 52-Week Lows On Friday
September 29, 2023
Friday's session saw 112 companies set new 52-week lows.
Via
Benzinga
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
September 15, 2023
Friday's session saw 169 companies set new 52-week lows.
Via
Benzinga
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
May 11, 2023
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'...
Via
Benzinga
Earnings Scheduled For May 8, 2023
May 08, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
Via
Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
Theravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off Staff
February 28, 2023
Via
Benzinga
Earnings Scheduled For February 27, 2023
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.